ExCEEd Orphan
PrivateLast Round
Strategic
Aug 1, 2022
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ExCEEd Orphan is a biopharmaceutical services company that provides market access, regulatory, and commercialization solutions for rare disease treatments in Central and Eastern Europe.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Compliance, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ExCEEd Orphan Comparables
Compare ExCEEd Orphan with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avanzanite Bioscience | 85% | |
| Swixx BioPharma | 79% | |
| Partner Rare | 78% | |
ExCEEd Orphan Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Aug 1, 2022 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 109% MoM.
- Mar 3, 2026
Monthly visitors grew 382% MoM, from 259 to 1.2K.
ExCEEd Orphan Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ExCEEd Orphan's valuation, stock price, and market status.